MedTrace Logo

The Prevention Options for Women Evaluation Research (POWER) Cohort

NCT03490058 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2255

Last updated 2021-12-06

No results posted yet for this study

Summary

The POWER Cohort study is a PrEP implementation project to demonstrate Pre-exposure prophylaxis (PrEP) delivery for young women in Cape Town and Johannesburg, South Africa and Kisumu, Kenya.

Conditions

Interventions

DRUG

Truvada

A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.

Sponsors & Collaborators

  • Desmond Tutu HIV Foundation

    collaborator OTHER

  • Wits Reproductive Health and HIV Institute

    collaborator OTHER

  • Kenya Medical Research Institute

    collaborator OTHER

  • United States Agency for International Development (USAID)

    collaborator FED

  • RTI International

    collaborator OTHER

  • Harvard Medical School (HMS and HSDM)

    collaborator OTHER

  • University of Pittsburgh

    collaborator OTHER

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • University of Washington

    lead OTHER

Principal Investigators

  • Connie L Celum, MD, MPH · University of Washington

  • Jared M Baeten, MD, PhD · University of Washington

  • Rachel Johnson, MPH · University of Washington

Eligibility

Min Age
16 Years
Max Age
25 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-06-14
Primary Completion
2020-12-04
Completion
2021-07-23

Countries

  • Kenya
  • South Africa

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03490058 on ClinicalTrials.gov